STARPHARMA
14.9.2020 09:11:12 CEST | Business Wire | Press release
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.
The latest results confirm that when SPL7013 is applied at the concentration of the SPL7013 COVID-19 nasal spray, it has potent virucidal activity, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19.
These data expand on the previously announced (see previous ASX announcement - 25 August 2020) data showing that SPL7013 has potent antiviral activity and inhibits infection of host cells by SARS‑CoV-2 when the compound is applied to the cells either before or after exposure to the virus. Earlier testing also showed that SPL7013 has a very favourable and high selectivity index1 (up to ~2200), indicating potent antiviral efficacy with minimal cellular toxicity. The high selectivity index of SPL7013 compares very favourably with the selectivity index against SARS-CoV-2 reported in the literature of 279 for remdesivir and 55 for hydroxychloroquine.2,3
Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to be working with Professor Gallay to expedite the development of this important product. These latest data show that at clinically relevant concentrations (at the concentration of the SPL7013 COVID‑19 nasal spray), SPL7013 inactivates more than 99.9% of SARS-CoV-2, which represents a compelling feature for the product. This potent virucidal action is consistent with the activity seen for SPL7013 in other viruses, including HIV and HSV.”
Professor Gallay commented: “We have been working with Starpharma for a number of months now and are impressed with the antiviral data generated in our lab for SPL7013 against SARS-CoV-2. It is particularly exciting to see a product show such a potent and clear virucidal effect against this highly infectious virus, and for its antiviral activity to be present when SPL7013 is added either before or after exposure of cells to the virus.”
Dr Fairley added “Starpharma’s COVID-19 nasal spray has potential to be an important near-term preventative product, and given it is based on an already marketed active, its path to market is both faster and less complex than a completely new product. Another attractive feature of Starpharma’s SPL7013 COVID-19 nasal spray is that it is entirely complementary to other prevention measures such as PPE and vaccines. It also has special relevance where social distancing is not possible such as crowded environments and certain workplaces. The importance of having multiple preventative product strategies has been highlighted by the recent challenges with some vaccine trials. Starpharma’s topical antiviral nasal spray could play a role both prior to vaccines being available, and complementary to vaccines once available to further reduce risk.”
Starpharma is expediting the development of the SPL7013 nasal spray and has already completed reformulation, pilot product manufacture, selection of device and packaging components, identification of manufacturer and compiled regulatory documentation in preparation for submission (see previous ASX announcement - 25 August 2020) . The company has also commenced commercial discussions across a range of distribution channels and customer groups (e.g. B2B, online platforms) and expects that the product will be ready for market in 1H CY2021.
SPL7013 Mechanism of antiviral action
SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. As for other viruses inhibited by SPL7013, SARS-CoV-2 infects human cells by using the characteristic viral surface proteins, or “spikes”, to attach to receptor proteins on the surface of human cells and SPL7013 blocks this interaction.
About SPL7013 COVID-19 nasal spray
SPL7013 is a broad-spectrum antiviral with potent SARS-CoV-2 activity and is also the active in VivaGel® marketed products approved in UK, Europe, Asia, Canada, Australia, and New Zealand. SPL7013 acts early in the viral replication cycle and has virucidal activity against SARS-CoV-2 with antiviral activity evident when used either before or after exposure of cells to the virus. SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. SPL7013 has broad spectrum antiviral and virucidal effects, with activity demonstrated against a range of viruses, including HIV, herpes simplex virus (HSV), human papillomavirus (HPV), adenovirus, H1N1 influenza virus, hepatitis B virus (HBV) and Zika virus.
About Starpharma
Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Disclosure
This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.
1 Selectivity index is a ratio of antiviral activity to cellular toxicity. The higher the selectivity index, the theoretically safer and more effective a compound would be in humans.
2 Pizzorno, A., et al., 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 104878. Advance online publication. https://doi.org/10.1016/j.antiviral.2020.104878
3 Liu, J., et al., 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 6(16). https://doi.org/10.1038/s41421-020-0156-0
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 10:00:00 CET | Press release
New integration enables Claude users to send and track messages across SMS, RCS, MMS and Viber through Infobip. Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, deli
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 09:55:00 CET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
Oasis Networks Selects PacketLight for Burstable Wavelength Services17.11.2026 09:35:00 CET | Press release
PacketLight Networks, a provider of DWDM and OTN optical transport solutions, today announced that Oasis Networks has selected its 800G transport and OLS optical amplification platforms to support the development of burstable wavelength services in Portugal. PacketLight’s open transport architecture supports Oasis’ plans to allocate optical capacity through software as customer requirements change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117351242/en/ PacketLight’s 800G DWDM transport and OLS optical amplification support Oasis Networks’ Lisbon–Sines connection and the development of burstable wavelength services. The connection between Lisbon and Sines is now in place, with the Sines endpoint at Start Campus. A proof of concept on Oasis’ operational network demonstrated software-controlled optical path establishment and reconfiguration. PacketLight has also completed the design for future site interconnects around
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 09:27:00 CET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
